GLP-1 Agonists Semaglutide, Tirzepatide, Retatrutide Reduce Alcohol's Internal Effects in Rats
Background
Alcohol Use Disorder (AUD) is a complex chronic disease with significant global health burden, yet current treatments often have limited efficacy and high relapse rates. The interoceptive effects of alcohol—the internal bodily sensations and subjective feelings it produces—play a crucial role in its rewarding properties and contribute to alcohol-seeking behavior. This study addresses the critical knowledge gap regarding novel pharmacological strategies that can attenuate these reinforcing internal cues of alcohol, potentially offering new avenues for AUD treatment.
Results
The study revealed a dose-dependent attenuation of alcohol's interoceptive effects by all three GLP-1 receptor agonists. Semaglutide significantly reduced alcohol-induced conditioned place preference by 38% at 1.0 mg/kg compared to vehicle-treated controls (p<0.01). Tirzepatide demonstrated greater potency, achieving a 49% reduction in alcohol's discriminative stimulus effects at 0.3 mg/kg (p<0.001). The most pronounced effect was observed with Retatrutide, which attenuated alcohol's interoceptive cues by an impressive 62% at 0.3 mg/kg (p<0.001), indicating its superior efficacy. These beneficial effects were consistently observed in both male and female rats, suggesting a broad applicability across sexes. > Retatrutide, the triple GLP-1/GIP/Glucagon agonist, was the most effective compound, reducing alcohol's interoceptive effects by 62%, highlighting the potential of multi-receptor agonism.
Why It Matters
This study provides compelling evidence that GLP-1 receptor agonists, particularly the more potent multi-agonists, could represent a novel and effective therapeutic class for Alcohol Use Disorder (AUD). By attenuating the internal rewarding sensations of alcohol, these compounds offer a unique mechanism of action compared to existing AUD medications. Given the significant unmet need for effective AUD treatments, these findings strongly support further investigation into GLP-1 receptor agonists as potential pharmacotherapies for AUD in humans. Future research should focus on translating these preclinical results into human clinical trials, potentially starting with Phase I/II studies to assess safety and efficacy in individuals with AUD.